Receive The Newest Study Notifications

Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced the presentation of data updates on two clinical studies at the 15thInternational Conference on Malignant...

 Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the initiation of a Phase 1/2 study of...

Asieris, a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases, announced today the completion of enrollment for its APL-1202 Phase Ib trial in the US. This new...

Clinical investigators will study the safety and efficacy of this microvascular device designed to restore blood flow and reduce amputations resulting from below the knee peripheral artery disease Micro Medical Solutions (MMS), an innovator in the field of...

trials targeting PD-L1 and CD16 in patients with solid tumors NantKwest establishes a leading portfolio of off-the-shelf NK cells at clinical stage of development with three engineered NK92 cells in trials: CD16 targeted haNK, CD19/CD16 targeted t-haNK and now...

Safety data from all patients show that KB103 was well tolerated with no adverse events reported Five out of six wounds treated with KB103 in the Phase 2 trial closed 100% during the trial The average time to complete 100% wound closure on KB103 treated wounds in...

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that the Company has reached alignment with the...

- Approach informed by regulatory guidance and real-world clinical experience - Horizon Therapeutics plc (HZNP) today announced the initiation of a clinical trial evaluating KRYSTEXXA® (pegloticase injection) in combination with methotrexate as a strategy to increase...

Sophiris Bio Inc. (SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant...

 OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that, after reviewing global study data, the Independent Data Monitoring Committee (IDMC) saw no safety concerns and recommended the continuation of patient recruitment, without any...

Balixafortide is the most advanced and only CXCR4 antagonist in development in a pivotal Oncology global registration trial. Polyphor today announced the enrollment of the first patient in its FORTRESS clinical trial, the pivotal Phase III study evaluating...

Sanofi and Regeneron announce positive topline Phase 2 results for IL-33 antibody in asthma REGN3500 (SAR440340) monotherapy significantly reduced loss of asthma control and improved lung function compared to placebo PARIS and TARRYTOWN, NY – June 21, 2019 – Sanofi...

Data selected for oral presentation during a plenary session at AACR's Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy Conference Company to host investor event and webcast on Monday, July 22 Marker...

Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced that an abstract featuring data from the Phase 2b ORCA-1 trial has been accepted for oral presentation at the SRNT-E Annual Conference,...

- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of the registrational Phase 2 portion of its TRIDENT-1 clinical study of patients with ROS1+ advanced...

Eight posters including one oral presentation support ongoing research and clinical experience with Hizentra®, the first and only subcutaneous immunoglobulin (Ig) therapy approved to address the unique needs of CIDP patients. Presentations include new analysis from...

- AB-729 is a subcutaneously-administered RNAi agent targeting HBV replication and HBsAg antigen production - Supports corporate objective to combine AB-729 with AB-506, Arbutus’ proprietary oral capsid inhibitor WARMINSTER, Pa., June 20, 2019 (GLOBE NEWSWIRE) --...

Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug...

Cancer Prevention Pharmaceuticals, Inc. (CPP) recently reported results from its pivotal Phase 3 trial of CPP-1X/sul for adults with familial adenomatous polyposis (FAP) at the Digestive Disease Week annual conference in San Diego. FAP is a rare genetic disease that...

Today Florence announced assignment of U.S. Patent No. 10,319,479 by the United States Patent and Trademark Office for: "Remote Monitoring and Dynamic Document Management Systems and Methods." This patent covers how Florence's applications process essential clinical...